PDCD1 and melanoma: Moreover, Machiraju and colleagues found an association between high pre-treatment serum levels of sLAG-3 (but not sPD-1, sPD-L1 or sTIM-3) and resistance to anti-PD-1 therapy in melanoma patients [47].